Literature DB >> 6361561

Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations.

J H Chesebro, V Fuster, L R Elveback, I P Clements, H C Smith, D R Holmes, W T Bardsley, J R Pluth, R B Wallace, F J Puga.   

Abstract

To study the prevention of occlusion of aortocoronary-artery bypass grafts, we concluded a prospective, randomized, double-blind trial comparing long-term administration of dipyridamole (begun two days before operation) plus aspirin (begun seven hours after operation) with placebo in 407 patients. Results at one month showed a reduction in the rate of graft occlusion in patients receiving dipyridamole and aspirin. At vein-graft angiography performed in 343 patients (84 per cent) 11 to 18 months (median, 12 months) after operation, 11 per cent of 478 vein-graft distal anastomoses were occluded in the treated group, and 25 per cent of 486 were occluded in the placebo group. The proportion of patients with one or more distal anastomoses occluded was 22 per cent of 171 patients in the treated group and 47 per cent of 172 in the placebo group. All grafts were patent within a month of operation in 94 patients in the placebo group and 116 patients in the treated group; late development of occlusions was reduced from 27 per cent in the placebo group to 16 per cent in the treatment group. The results show that dipyridamole and aspirin continue to be effective in preventing vein-graft occlusion late after operation, and we believe that such treatment should be continued for at least one year.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6361561     DOI: 10.1056/NEJM198401263100401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  51 in total

Review 1.  Gene therapy for vein graft disease.

Authors:  D G Cable; H V Schaff
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Indirect comparison meta-analysis of aspirin therapy after coronary surgery.

Authors:  Eric Lim; Ziad Ali; Ayyaz Ali; Tom Routledge; Lyn Edmonds; Douglas G Altman; Stephen Large
Journal:  BMJ       Date:  2003-12-06

3.  AIDS prodrome in an apparently normal man following coronary artery bypass: new significance of postoperative bleeding.

Authors:  A P Weiland; Y Daskal; R Kerman; R W Smalling; J P Williams; W E Walker
Journal:  Tex Heart Inst J       Date:  1985-06

4.  Plasma drug and antiplatelet profiles of the original acetylsalicylic acid preparations used in the AMIS, PARIS and German-Austrian trials for secondary prevention of myocardial infarction.

Authors:  R Simrock; K Rehders; H Spahn; E Mutschler; H K Breddin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Pro: Should aspirin be continued after cardiac surgery in the setting of thrombocytopenia?

Authors:  Nauder Faraday
Journal:  J Cardiothorac Vasc Anesth       Date:  2006-02       Impact factor: 2.628

Review 6.  Use of novel antiplatelet agents in acute coronary syndromes.

Authors:  Michael Luna; Elizabeth M Holper
Journal:  Curr Atheroscler Rep       Date:  2015-03       Impact factor: 5.113

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

8.  [Low-dose acetylsalicylic acid (100 mg/day) following aortocoronary bypass operation].

Authors:  M Weber; C von Schacky; R Lorenz; W Meister; J Kotzur; B Reichart; K Theisen; P C Weber
Journal:  Klin Wochenschr       Date:  1984-05-15

Review 9.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

Review 10.  Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications.

Authors:  Christopher D Owens
Journal:  J Vasc Surg       Date:  2009-10-17       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.